AI-assisted, human-published

05/06/2025 /Funding Events

NewLimit Secures $130M Series B to Develop Anti-Aging Medicine

Biotech startup NewLimit raises $130 million to advance research in anti-aging medicine and cell reprogramming, while utilizing AI for drug development.

 

AI-assisted, human-published

Latest headlines







join us

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here

©2023 VentureCapital.com